Syngene International Ltd
SYNGENESyngene International Ltd
SYNGENE
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 66.42 | 8.88 | 0.16% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.65 | 4.77 | 0.76% |
Forecast & Ratings
Detailed Forecastfrom 8 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.
Investor Presentation
View olderPeers
Compare with peersDivi's Laboratories Ltd
Aarti Pharmalabs Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Vaidya Sane Ayurved Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 871.60 | 1,113.30 | 1,294.50 | 1,484.90 | 1,900.70 | 2,164.80 | 2,283.90 | 2,711.80 | 3,263.80 | 3,435.50 | ||||||||||
Raw Materials | 249.30 | 314.80 | 321.20 | 395.20 | 505.30 | 518.60 | 551.70 | 770.60 | 902.20 | 2,383.00 | ||||||||||
| Power & Fuel Cost | 27.50 | 30.80 | 30.40 | 34.70 | 41.30 | 45.80 | 57.40 | 64.80 | 69.20 | |||||||||||
| Employee Cost | 201.90 | 249.30 | 308.60 | 379.60 | 472.70 | 580.40 | 660.20 | 718.10 | 841.70 | |||||||||||
| Selling & Administrative Expenses | 43.30 | 51.10 | 66.40 | 116.20 | 123.10 | 123.80 | 107.80 | 137.60 | 196.70 | |||||||||||
| Operating & Other expenses | 56.80 | 80.60 | 89.60 | 32.60 | 146.40 | 125.40 | 135.40 | 202.50 | 248.70 | |||||||||||
EBITDA | 292.80 | 386.70 | 478.30 | 526.60 | 611.90 | 770.80 | 771.40 | 818.20 | 1,005.30 | 1,052.50 | ||||||||||
| Depreciation/Amortization | 81.40 | 97.30 | 114.30 | 131.40 | 164.20 | 219.30 | 274.50 | 309.70 | 366.50 | 382.50 | ||||||||||
| PBIT | 211.40 | 289.40 | 364.00 | 395.20 | 447.70 | 551.50 | 496.90 | 508.50 | 638.80 | 670.00 | ||||||||||
| Interest & Other Items | 7.90 | 8.40 | 17.50 | 22.70 | 32.30 | 34.60 | 27.70 | 24.10 | 45.20 | 46.30 | ||||||||||
| PBT | 203.50 | 281.00 | 346.50 | 372.50 | 415.40 | 516.90 | 469.20 | 484.40 | 593.60 | 623.70 | ||||||||||
| Taxes & Other Items | 28.50 | 40.20 | 59.20 | 67.10 | 83.80 | 104.80 | 64.30 | 88.60 | 129.20 | 139.90 | ||||||||||
| Net Income | 175.00 | 240.80 | 287.30 | 305.40 | 331.60 | 412.10 | 404.90 | 395.80 | 464.40 | 483.80 | ||||||||||
| EPS | 2.29 | 4.03 | 7.18 | 7.63 | 8.29 | 10.30 | 10.12 | 9.89 | 11.58 | 12.05 | ||||||||||
| DPS | 10.50 | 0.50 | 0.50 | 0.50 | 0.25 | 0.00 | 0.00 | 1.00 | 1.25 | 2.25 | ||||||||||
| Payout ratio | 4.59 | 0.12 | 0.07 | 0.07 | 0.03 | 0.00 | 0.00 | 0.10 | 0.11 | 0.19 |
Company Updates
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Syngene International Ltd | 69.20 | 8.88 | 0.16% |
| Divi's Laboratories Ltd | 54.82 | 7.83 | 0.80% |
| Aarti Pharmalabs Ltd | 21.64 | 2.69 | — |
| Dishman Carbogen Amcis Ltd | -85.52 | 0.44 | — |
Price Comparison
Compare SYNGENE with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 10.06%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Syngene International Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Mirae Asset Focused Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8931% | Percentage of the fund’s portfolio invested in the stock 3.00% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/32 (+1) |
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7697% | Percentage of the fund’s portfolio invested in the stock 0.93% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 35/65 (+1) |
ICICI PRUDENTIAL LONG TERM EQUITY FUND (TAX SAVING) DIRECT PLAN - GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6984% | Percentage of the fund’s portfolio invested in the stock 1.93% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/53 (-1) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Syngene International Ltd
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹0.75
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJul 16, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Jul 16, 2019
News & Opinions
News Video
Laurus Labs, Syngene, Ipca, Gland Pharma Report Export Growth In August | BQ Prime
2 weeks ago•BQ Prime
Biocon names Peter Bains as group CEO, will report to Kiran Mazumdar-Shaw
2 weeks ago•Business Today
Syngene Q1 Results Review - Healthy Guidance Already Priced In: Yes Securities
2 months ago•Bloomberg Quint
News Video
Strong Show From Syngene Int'l In Q1 | Jonathan Hunt Explains | Business News | ET Now
2 months ago•ET NOW
Syngene International gains 6% on healthy Q1 numbers
2 months ago•Moneycontrol
Syngene International Q1FY24: Net profit up 26%, revenue surges 25.4%
2 months ago•Moneycontrol
Syngene’s Q1 net profits up 26% to ₹93 crore
2 months ago•The Hindu Businessline
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.06%, vs industry avg of 8.01%
Increasing Market Share
Over the last 5 years, market share increased from 13.99% to 18.55%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 8.74%, vs industry avg of 14.98%